SSA
PCVX icon

Schonfeld Strategic Advisors’s Vaxcyte PCVX Stock Holding History

Schonfeld Strategic Advisors’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-15,000
Closed -$566K – 2414
2025
Q1 		$566K Buy
+15,000
New +$1.2M ﹤0.01% 1531

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Schonfeld Strategic Advisors's PCVX Position: Q4 2025 in Review

Schonfeld Strategic Advisors sold out of Vaxcyte (PCVX) in Q4 2025, closing a stake of 28,761 shares — an estimated $1.04M sold.

Schonfeld Strategic Advisors first reported a position in PCVX in Q3 2022 and held it in 13 quarters. The position peaked at $13.6M in Q3 2023. 295 funds tracked by Wall St. Rank hold PCVX as of Q4 2025.

  • Schonfeld Strategic Advisors reported no remaining Vaxcyte position as of Q4 2025 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 28,761 Vaxcyte shares in Q4 2025, an estimated $1.04M.
  • Schonfeld Strategic Advisors first reported a position in Vaxcyte in Q3 2022 and held it in 13 quarters.
  • Schonfeld Strategic Advisors's Vaxcyte position peaked at $13.6M in Q3 2023.
  • 295 funds tracked by Wall St. Rank held Vaxcyte as of Q4 2025.

Based on Schonfeld Strategic Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.